HK Stock Market Move | INNOVENT BIO(01801) now falls by nearly 4% as the company makes one-time provisions for channel inventory. Institutions state that the performance in the fourth quarter still meets expectations.

INNOVENT BIO (01801) is currently down nearly 4%, at the time of writing, down 3.72% to HK$77.65, with a turnover of HK$5.19 billion. In terms of news, INNOVENT BIO announced that in the full year of 2025, the company achieved a total product revenue of about RMB 11.9 billion, a year-on-year increase of 45%, and it broke through the milestone of RMB 10 billion for the first time. In the fourth quarter, the company achieved a total product revenue of about RMB 3.3 billion, a year-on-year increase of over 60%, continuing the strong growth momentum. It is worth noting that in the fourth quarter of 2025, due to six new drugs being included in the 2026 national medical insurance catalog for the first time, INNOVENT BIO distributed products to channels at the original price and made a one-time inventory compensation. HAITONG INT'L stated that considering the one-time provision for channel inventory, the institution believes that the company's performance in the fourth quarter is in line with expectations and is optimistic about the accelerated volume increase after the six new drugs are included in the medical insurance catalog.